臨床試驗

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT：NCT07073950 · RECRUITING

NCT IDNCT07073950

狀態RECRUITING

開始日期2025-11-24

完成時間2027-05-31

SponsorAstraZeneca (INDUSTRY)

First posted2025-07-20

Last updated2026-09-18

簡要摘要

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。